Ergoteles LLC Lowers Stake in Spruce Biosciences, Inc. (NASDAQ:SPRB)

Ergoteles LLC lowered its position in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Rating) by 45.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,032 shares of the company’s stock after selling 18,868 shares during the quarter. Ergoteles LLC’s holdings in Spruce Biosciences were worth $32,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Bailard Inc. purchased a new position in shares of Spruce Biosciences in the third quarter worth $29,000. Goldman Sachs Group Inc. lifted its holdings in shares of Spruce Biosciences by 39.7% in the second quarter. Goldman Sachs Group Inc. now owns 59,609 shares of the company’s stock worth $104,000 after buying an additional 16,941 shares in the last quarter. Renaissance Technologies LLC increased its position in Spruce Biosciences by 180.7% in the first quarter. Renaissance Technologies LLC now owns 111,700 shares of the company’s stock worth $225,000 after purchasing an additional 71,900 shares during the last quarter. Bank of New York Mellon Corp increased its position in Spruce Biosciences by 317.7% in the first quarter. Bank of New York Mellon Corp now owns 116,501 shares of the company’s stock worth $234,000 after purchasing an additional 88,608 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Spruce Biosciences in the second quarter worth $331,000. Hedge funds and other institutional investors own 84.21% of the company’s stock.

Spruce Biosciences Trading Up 0.4 %

SPRB stock opened at $2.38 on Friday. The company has a quick ratio of 7.76, a current ratio of 7.76 and a debt-to-equity ratio of 0.05. Spruce Biosciences, Inc. has a twelve month low of $0.95 and a twelve month high of $3.57. The stock has a market capitalization of $56.07 million, a price-to-earnings ratio of -1.27 and a beta of 2.32. The firm’s fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $1.73.

Analyst Ratings Changes

Several brokerages recently weighed in on SPRB. Oppenheimer reduced their price target on shares of Spruce Biosciences from $13.00 to $8.00 and set an “outperform” rating on the stock in a research report on Thursday, November 17th. JMP Securities began coverage on shares of Spruce Biosciences in a research report on Wednesday, November 16th. They issued a “market outperform” rating and a $8.00 price target on the stock. Finally, Royal Bank of Canada reduced their price target on shares of Spruce Biosciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Monday, February 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.40.

Spruce Biosciences Company Profile

(Get Rating)

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.